Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator.

[1]  I. Thompson,et al.  The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape. , 2015, The Journal of urology.

[2]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Peters,et al.  Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. , 2014, The Lancet. Oncology.

[4]  Lori J Sokoll,et al.  Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. , 2014, Urology.

[5]  S. Eggener,et al.  Development and multi‐institutional validation of an upgrading risk tool for Gleason 6 prostate cancer , 2013, Cancer.

[6]  L. Marks.  Improving risk stratification in patients with prostate cancer managed by active surveillance: a nomogram predicting the risk of biopsy progression. , 2013 .

[7]  M. Roobol,et al.  Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. , 2013, European urology.

[8]  John T. Wei,et al.  Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study , 2013, Clinical Cancer Research.

[9]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[10]  M. Roobol,et al.  Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. , 2012, European urology.

[11]  B. Trock,et al.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.

[12]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[13]  Yuanyuan Liang,et al.  Updating risk prediction tools: A case study in prostate cancer , 2012, Biometrical journal. Biometrische Zeitschrift.

[14]  A. Partin,et al.  Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Carroll,et al.  Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. , 2010, Urology.

[17]  J. Moul,et al.  Prostate cancer: the new landscape , 2009, Current opinion in urology.

[18]  E. Klein,et al.  Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer , 2009, BJU international.

[19]  Dante diTommaso,et al.  Quantifying the role of PSA screening in the US prostate cancer mortality decline , 2008, Cancer Causes & Control.

[20]  J. Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[21]  M. Cooperberg,et al.  The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Partin,et al.  Expectant management of localized prostate cancer. , 2003, Urology.

[23]  I. Thompson,et al.  Expectant management of localized prostatic cancer , 1991, Cancer.

[24]  Liying Zhang,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.